Strategic partnerships ImmuPharma is actively forming external manufacturing partnerships for Kapiglucagon with industry leaders like Thermo Fisher Scientific for drug product CDMO and Bachem for API manufacturing, presenting opportunities for co-development, supply chain collaborations, and scale-up services.

Pipeline acceleration With Kapiglucagon targeting type 1 diabetes and having a fast track regulatory pathway, there is potential to explore joint development agreements, funding collaborations, and risk-sharing deals to accelerate clinical milestones and commercialization.

Funding readiness Recent fundraising activity and a $23M funding base indicate openness to strategic financing and investor-backed partnerships; consider SPAC-style or equity-linked partnerships, milestone-based financing, and convertible debt discussions.

Clinical focus Lead program P140 as an immune tolerance restorer for SLE and CIDP suggests opportunities to cross-sell or co-develop ancillary autoimmune indications, as well as services for translational research, biomarker collaboration, and contract research.

Small team leverage With a compact team and ongoing external collaborations, there is a strong need for scalable CRO/CDMO partnerships, advisory services, and white-label development programs to extend capabilities without increasing internal headcount.